Table 1.
Clinical features of breast tumors analyzed for miR-944 expression
| Patient | Tumor size (mm) | Clinical stage | Tumor grade | HER2 | ER | PR | Classification | Histological subtype |
|---|---|---|---|---|---|---|---|---|
| 5 | 30 | IIIB | ND | + | - | - | Her2+ | Infiltrating ductal carcinoma |
| 13 | 15 | I | ND | - | + | + | Luminal A | In situ papillary carcinoma |
| 24 | 25 | IIA | ND | + | - | - | Her2+ | Infiltrating papillary carcinoma |
| 50 | 25 | IIA | 2 | - | + | + | Luminal A | Infiltrating ductal carcinoma |
| 55 | 20 | I | 3 | + | - | - | Her2+ | Infiltrating ductal carcinoma |
| 58 | 35 | IIA | 2 | + | - | - | Her2+ | In situ ductal carcinoma |
| 59 | ND | ND | 2 | - | + | + | Luminal A | Infiltrating ductal carcinoma |
| 71 | 19 | IIIA | 2 | - | + | - | Luminal A | Infiltrating ductal carcinoma |
| 73 | 20 | IIIA | ND | + | + | + | Luminal B | Infiltrating ductal carcinoma |
| 74 | 35 | IIB | ND | - | - | + | ND | Infiltrating ductal carcinoma |
| 79 | 20 | IIIB | 2 | - | + | - | Luminal A | Infiltrating ductal carcinoma |
| 80 | 25 | IIA | 3 | - | - | - | Triple negtive | Infiltrating ductal carcinoma |
| 81 | 25 | IIA | 3 | - | - | + | ND | Infiltrating ductal carcinoma |
| 82 | 25 | IIB | ND | + | - | - | Luminal A | Infiltrating ductal carcinoma |
| 97 | 47 | IIIA | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 98 | 20 | I | ND | - | + | - | Luminal A | Infiltrating ductal carcinoma |
| 106 | 16 | I | ND | - | + | + | Luminal A | Infiltrating ductal carcinoma |
| 107 | 20 | I | 2 | - | + | + | Luminal A | Infiltrating ductal carcinoma |
| 110 | 25 | IIA | 2 | - | + | - | Luminal A | Infiltrating ductal carcinoma |
| 113 | 17 | I | 1 | - | + | + | Luminal A | In situ lobular carcinoma |
| 122 | 16 | IIA | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 125 | 25 | IIB | 2 | - | + | - | Luminal A | Infiltrating ductal carcinoma |
| 128 | 22 | IIA | ND | - | + | + | Luminal | Infiltrating mucinous carcinoma |
| 129 | 13 | IIA | ND | - | + | + | Luminal A | Infiltrating ductal carcinoma |
| 139 | 30 | IIB | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 142 | 18 | IIA | ND | - | - | + | ND | Infiltrating lobular carcinoma |
| 144 | 35 | IIB | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 146 | 65 | IIIB | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 149 | 30 | IIB | 2 | - | + | - | Luminal A | Infiltrating ductal carcinoma |
| 150 | 10 | 0 | 1 | - | + | + | Luminal A | In situ ductal carcinoma |
| 168 | 40 | IIB | 2 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 186 | 45 | IIB | 2 | - | + | + | Luminal A | Infiltrating ductal carcinoma |
| 189 | 40 | IIB | ND | - | - | - | Triple negative | Infiltrating medular carcinoma |
| 2b | 55 | IIIA | ND | - | - | - | Triple negative | Infiltrating lobular carcinoma |
| 3b | 10 | I | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 4b | 11 | I | 1 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 7b | ND | ND | ND | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 8b | 17 | I | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 9b | 30 | IIA | 2 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
| 10b | 27 | IIB | 3 | - | - | - | Triple negative | Infiltrating ductal carcinoma |
ND, No determined; ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human epidermal growth factor receptor 2